Kadmon biopharma shares rise on interim trial results

Shares of Kadmon Holdings are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary endpoint in a trial. Chronic graft-versus-host disease is a rare condition that can occur after a transplant. Kadmon said it expects to file the experimental therapy with the U.S. Food and Drug Administration next year. Its stock is up 58.65% year-to-date, while the S&P 500 has gained 23%. While the ORR endpoint was met at the interim analysis, the primary analysis of the KD025-213 study will occur in the first quarter of 2020, six months after completion of enrollment. This analysis will include updated safety data and efficacy data, including ORRs and secondary endpoints, such as duration of response, changes in corticosteroid dose and changes in quality of life. Kadmon plans to submit results from the KD025-213 study for presentation at an upcoming scientific meeting.

https://finance.yahoo.com/m/6de3caeb...html?.tsrc=rss